GOVX Stock Soars 80%: Retail Traders Are Piling In As Ebola, Hantavirus Risks Resurface

• GeoVax said recent WHO outbreak developments reinforce the need for stronger pandemic preparedness.
• The biotech firm said European regulators backed GEO-MVA’s path toward a late-stage Phase 3 trial later this year.
• The company also said it is scaling vaccine manufacturing capabilities through its AGE1 production platform.

Shares of GeoVax Labs, Inc. (GOVX) staged a massive 80% rally on Monday as the company pushed its vaccine platform amid mounting global concerns over Ebola outbreaks, mpox spread and hantavirus.

GOVX stock logged its best day in nearly two years on Monday, but slipped 9% in extended trading as plans for a stock offering sparked dilution fears among traders. 

GeoVax Pushes GEO-MVA Vaccine Program

GeoVax said that recent public health developments, including the World Health Organization’s (WHO) declaration of a Public Health Emergency of International Concern from the ongoing Bundibugyo Ebola outbreak, the continued spread of Clade I mpox and recent hantavirus-related concerns, highlight the need for stronger pandemic preparedness.

The WHO on Monday opened its annual World Health Assembly in Geneva, and warned about the increasing strain on international healthcare systems from the outbreaks.

“GeoVax’s primary strategic focus remains the advancement of GEO-MVA, our Modified Vaccinia Ankara (MVA) mpox and smallpox vaccine candidate, which we believe is well aligned with growing global emphasis on diversified vaccine supply, domestic manufacturing capability, and long-term biodefense preparedness,” said GeoVax CEO David A. Dodd.

GeoVax Prepares Vaccine Supplies For Phase 3

GeoVax said European regulators recently gave positive feedback for GEO-MVA, the company’s mpox and smallpox vaccine candidate, helping clear the path for a late-stage Phase 3 trial that could help with future approval.

The company expects to begin the study later this year, with results expected by mid-2027. The trial will include around 500 participants and will compare immune responses generated by GEO-MVA against an already approved MVA-based vaccine to determine whether it produces similar protective antibody levels. GeoVax also said it has already completed key manufacturing work and prepared clinical trial vaccine supplies needed for the next stage of testing.

Meanwhile, the company is also scaling up its manufacturing capabilities through its AGE1 production platform, which will drive larger vaccine output in the future if demand rises. GeoVax also highlighted earlier Ebola-related research involving its MVA vaccine platform, saying that preclinical studies showed complete protection in non-human primates exposed to the Ebola virus.

GeoVax Raises Fresh Capital 

Separately, GeoVax also announced a securities purchase agreement with existing institutional investors expected to generate $3 million in gross proceeds before fees and expenses. The financing includes the sale of 2.03 million shares, alongside Series A and Series B warrants with exercise prices of $1.48 per share.

GeoVax said the proceeds will be used for working capital and general corporate purposes.

GeoVax Builds Broader Biotech Pipeline

Beyond infectious disease programs, GeoVax is also advancing Gedeptin, a cancer treatment that helps the immune system respond more effectively to head and neck tumors. The company recently expanded the program through an exclusive licensing agreement with Emory University focused on combining Gedeptin with checkpoint inhibitor therapies, a widely used class of cancer immunotherapy drugs.

GeoVax is also continuing development of GEO-CM04S1, its COVID-19 vaccine candidate, which is being evaluated for immunocompromised patients and other higher-risk populations.

How Do Retail Traders Feel About GOVX?

On Stocktwits, retail sentiment for GOVX jumped to ‘extremely bullish’ from ‘bearish’ levels a day ago amid a massive 71,900% surge in 24-hour message volumes.

One user said, “$GOVX  this has “underestimated” written all over it.”

Another bullish user said, “$GOVX Holding for sure. Not many shares 1000 but not letting them go for now.”

GOVX stock has declined 91% over the past year and is down 48% since January. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: SpaceX IPO Frenzy Gets Fresh AI Fuel: Elon Musk Cheers Nvidia Vera CPU For Training Smarter AI Models